Seven tumor antigens (ADA, FYN, HDC, NFKBIZ, RASSF4, SLC6A3, and UPP1) associated with inferior prognoses and higher-level infiltration of antigen-presenting cells in PRAD were identified, thus promising candidates for mRNA vaccine. The gene discussed is RASSF4; the disease is prostate adenocarcinoma.